The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection

BACKGROUND:  Successful hepatitis C virus (HCV) treatment may reduce cardiovascular disease (CVD) risk and improve levels of CVD biomarkers produced outside the liver (nonhepatic biomarkers). METHODS:  Stored serum or plasma from before and 24 weeks after end of HCV treatment (EOT) from human immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Chew, Kara W., Hua, Lei, Bhattacharya, Debika, Butt, Adeel A., Bornfleth, Lorelei, Chung, Raymond T., Andersen, Janet W., Currier, Judith S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324212/
https://www.ncbi.nlm.nih.gov/pubmed/25734172
http://dx.doi.org/10.1093/ofid/ofu104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324212/
https://www.ncbi.nlm.nih.gov/pubmed/25734172
http://dx.doi.org/10.1093/ofid/ofu104

Ejemplares similares